Medulloblastoma Clinical Trials

124 clinical trials for Medulloblastoma across international registries, including 24 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma — RECRUITING · PHASE2
• PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications — RECRUITING · PHASE1
• Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma — RECRUITING · NA
• Atovaquone Combined With Radiation in Children With Malignant Brain Tumors — RECRUITING · PHASE1
• Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors — RECRUITING · PHASE1
• Digoxin Medulloblastoma Study — RECRUITING · PHASE2
• CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation — RECRUITING
• Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma — RECRUITING
• Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). — RECRUITING · PHASE1
• Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors — RECRUITING · PHASE1
• Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma — RECRUITING · PHASE2
• GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults — RECRUITING · PHASE1
• Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer — RECRUITING · PHASE1
• Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms — RECRUITING · PHASE1
• 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. — RECRUITING · PHASE4
• A PHASE 3 STUDY OF SODIUM THIOSULFATE FOR REDUCTION OF CISPLATIN-INDUCED OTOTOXICITY IN CHILDREN WITH AVERAGE-RISK MEDULLOBLASTOMA AND REDUCED THERAPY IN CHILDREN WITH MEDULLOBLASTOMA WITH LOW-RISK FEATURES — RECRUITING · PHASE3
• Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline — RECRUITING
• Intraoperatively Observed Site of Origin and Growth Pattern of Medulloblastoma — RECRUITING
• PHASE II TRIAL OF EFLORNITHINE/DFMO AS MAINTENANCE THERAPY FOR MOLECULAR HIGH RISK/VERY HIGH RISK AND RELAPSED/REFRACTORY MEDULLOBLASTOMA — RECRUITING · PHASE2
• Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China — RECRUITING
• PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF METFORMIN FOR COGNITIVE RECOVERY AND WHITE MATTER GROWTH IN PAEDIATRIC PATIENTS WITH A BRAIN TUMOUR — RECRUITING · PHASE3
• A PHASE 2 STUDY OF REDUCED THERAPY FOR NEWLY DIAGNOSED AVERAGE-RISK WNT-DRIVEN MEDULLOBLASTOMA PATIENTS — RECRUITING · PHASE2
• NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO EITHER SINGLE-CYCLE OR TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE — RECRUITING
• A CLINICAL AND MOLECULAR RISK-DIRECTED THERAPY FOR NEWLY DIAGNOSED MEDULLOBLASTOMA — RECRUITING
• Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor — COMPLETED · PHASE2
• Phase I Study of APX005M in Pediatric Central Nervous System Tumors — COMPLETED · PHASE1
• Rare CNS Tumors Outcomes &Risk — COMPLETED
• Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors — COMPLETED
• Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models — COMPLETED
• Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY — NOT_YET_RECRUITING · PHASE1
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors — NOT_YET_RECRUITING
• PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma — SUSPENDED · PHASE1
• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma — ACTIVE_NOT_RECRUITING · PHASE2
• Targeting MYC in High-Risk Medulloblastoma — NOT_YET_RECRUITING · NA
• Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Methionine PET/CT Studies In Patients With Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma — COMPLETED · PHASE3
• Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET — COMPLETED · PHASE3
• HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors — ACTIVE_NOT_RECRUITING · PHASE4
• A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma — ACTIVE_NOT_RECRUITING · PHASE1
• Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease — NOT_YET_RECRUITING · PHASE1
• An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition — TERMINATED · PHASE3
• Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors — NOT_YET_RECRUITING
• DOTATOC PET/CT for Imaging NET Patients — ACTIVE_NOT_RECRUITING
• Pharmacoscopy for Patients With Refractory Primary Brain Tumors — NOT_YET_RECRUITING · PHASE2
• Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors — TERMINATED
• my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults — NOT_YET_RECRUITING · NA
• Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma — ACTIVE_NOT_RECRUITING · PHASE1

Refine this search